about
Is Oxytocin Application for Autism Spectrum Disorder Evidence-Based?Naturalistic Pharmacotherapy Compliance among Pediatric Patients with Attention Deficit/Hyperactivity Disorder: a Study Based on Three-Year Nationwide DataAdvanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD).Effects of atomoxetine on hyper-locomotive activity of the prenatally valproate-exposed rat offspringChanges of empathy in medical college and medical school students: 1-year follow up study.Factors that Affect the Adherence to ADHD Medications during a Treatment Continuation Period in Children and Adolescents: A Nationwide Retrospective Cohort Study Using Korean Health Insurance Data from 2007 to 2011Supplementation of Korean Red Ginseng improves behavior deviations in animal models of autismA Multicenter Study Investigating Empathy and Burnout Characteristics in Medical Residents with Various Specialties.Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.Myasthenia gravis, schizophrenia, and colorectal cancer in a patient: long-term follow-up with medication complexity.A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder.Prescription Trends of Psychotropics in Children and Adolescents with Autism Based on Nationwide Health Insurance Data.Nationwide rate of attention-deficit hyperactivity disorder diagnosis and pharmacotherapy in Korea in 2008-2011.Valproic Acid Induces Telomerase Reverse Transcriptase Expression during Cortical Development.The relationship between microstructural alterations of the brain and clinical measurements in children and adolescents with hair pulling disorder.Berberine Ameliorates Brain Inflammation in Poloxamer 407-Induced Hyperlipidemic Rats
P50
Q26771760-DDD7399A-063A-40F0-AA33-7A7BE427B942Q31070157-EE74D5DE-5AFD-4BB0-9743-C2E3EAB4899BQ33618938-9C59912D-179E-461A-B4D1-9745AB0E95D0Q34278294-BAF7505E-87D9-4976-961E-018928000B9DQ34360515-919DB1D6-1C17-461B-A37B-512555EF5D0BQ34514197-4E945EA7-DFE1-4F44-B751-3E6714AEA05AQ36317152-A99ADFB8-1972-4374-859F-9858F024E0E7Q36534179-EA84F31A-5582-48EA-AF63-53B6933375FBQ36735852-FA96A742-48F8-479C-80EC-195BD984A60DQ37110515-459E9127-A391-43C5-B670-1E8DED4D1CC3Q37348827-BAAAFEBE-4A50-41EA-A230-68DC35C2E916Q38437097-16D8F84B-8FC6-4E19-BBD4-2F7D2EAC66A4Q41648983-BA456447-ECB4-4DFF-A58E-AB7118DE7F29Q43747165-8CE56AFC-2720-464C-8656-1D10FE74C51DQ47138840-6B6644B9-D2EF-46F8-BDB8-5E0DC0D74568Q48238794-8ECA68D9-2FD1-4507-982C-9813B79572B4Q91647643-3C9957CC-C803-408F-9828-FB46710D55A1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Minha Hong
@ast
Minha Hong
@en
Minha Hong
@es
Minha Hong
@nl
Minha Hong
@sl
type
label
Minha Hong
@ast
Minha Hong
@en
Minha Hong
@es
Minha Hong
@nl
Minha Hong
@sl
prefLabel
Minha Hong
@ast
Minha Hong
@en
Minha Hong
@es
Minha Hong
@nl
Minha Hong
@sl
P106
P31
P496
0000-0003-4924-1107